Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

MorphoSys AG. (12/8/14). "Press Release: MorphoSys Presents Updated Phase 2 Clinical Results for MOR208 Monotherapy in NHL at American Society of Hematology Meeting. DLBCL and FL Identified as Particularly Promising Indications".

Organisations Organisation MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group MorphoSys (Group)
  Organisation 2 American Society of Hematology (ASH)
Products Product MOR208 (MorphoSys/Xencor, formerly XmAb5574)
  Product 2 clinical research
Persons Person Schottelius, Arndt (Kymab 201806 EVP RnD before MorphoSys 200812–201701 Chief Developm Officer before Genentech)
  Person 2 Gutjahr-Löser, Claudia (MC Services 201710– Managing Director before MorphoSys 2002–2017 + Cassiopeia + Deutsche Bank)
     


   
Record changed: 2017-04-02

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top